Biodexa Pharmaceuticals (BDRX) Receivables (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Receivables of $5.0 million for Q4 2025, down 16.0% sequentially from $6.0 million in Q2 2025, and down 40.26% YoY from $8.4 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Receivables (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Receivables for 13 years, with the latest figure at $5.0 million in Q4 2025.
- Quarterly Receivables fell 40.26% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (down 40.26% YoY) and the FY2025 annual result came in at $5.0 million, down 40.78% from the prior year.
- Receivables retreated to $5.0 million in Q4 2025 per BDRX's latest filing, from $6.0 million in the prior quarter.
- Over five years, Receivables peaked at $8.4 million in Q4 2024 and troughed at $790613.8 in Q4 2023.
- A 5-year average of $3.0 million and a median of $1.8 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2024: Receivables tumbled 57.08% in 2021, then soared 966.27% in 2024.
- Over 5 years, Receivables stood at $1.4 million in 2021, then declined by 15.34% to $1.2 million in 2022, then plunged by 33.0% to $790613.8 in 2023, then jumped by 966.27% to $8.4 million in 2024, then plunged by 40.26% to $5.0 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $5.0 million, $6.0 million, and $8.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 65,947.56 | -11.29 Mn | - | 5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.04 Mn |
| Jun 30, 2025 | 6.00 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Dec 31, 2023 | 790,613.75 |
| Jun 30, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Jun 30, 2021 | 1.96 Mn |
| Dec 31, 2020 | 755,297.97 |
| Jun 30, 2020 | 4.56 Mn |
| Dec 31, 2019 | 1.28 Mn |
| Jun 30, 2019 | 3.30 Mn |
| Dec 31, 2018 | 1.70 Mn |
| Jun 30, 2018 | 979,533.13 |
| Dec 31, 2017 | 4.30 Mn |
| Jun 30, 2017 | 3.30 Mn |
| Dec 31, 2016 | 3.03 Mn |
| Jun 30, 2016 | 2.16 Mn |